Pharmacologic therapy for type 2 diabetes mellitus - PubMed (original) (raw)
Review
Pharmacologic therapy for type 2 diabetes mellitus
R A DeFronzo. Ann Intern Med. 1999.
Abstract
Type 2 diabetes mellitus is a chronic metabolic disorder that results from defects in both insulin secretion and insulin action. An elevated rate of basal hepatic glucose production in the presence of hyperinsulinemia is the primary cause of fasting hyperglycemia; after a meal, impaired suppression of hepatic glucose production by insulin and decreased insulin-mediated glucose uptake by muscle contribute almost equally to postprandial hyperglycemia. In the United States, five classes of oral agents, each of which works through a different mechanism of action, are currently available to improve glycemic control in patients with type 2 diabetes. The recently completed United Kingdom Prospective Diabetes Study (UKPDS) has shown that type 2 diabetes mellitus is a progressive disorder that can be treated initially with oral agent monotherapy but will eventually require the addition of other oral agents, and that in many patients, insulin therapy will be needed to achieve targeted glycemic levels. In the UKPDS, improved glycemic control, irrespective of the agent used (sulfonylureas, metformin, or insulin), decreased the incidence of microvascular complications (retinopathy, neuropathy, and nephropathy). This review examines the goals of antihyperglycemic therapy and reviews the mechanism of action, efficacy, nonglycemic benefits, cost, and safety profile of each of the five approved classes of oral agents. A rationale for the use of these oral agents as monotherapy, in combination with each other, and in combination with insulin is provided.
Similar articles
- New oral therapies for type 2 diabetes.
Purnell JQ, Hirsch IB. Purnell JQ, et al. Am Fam Physician. 1997 Nov 1;56(7):1835-42. Am Fam Physician. 1997. PMID: 9371013 Review. - The use of insulin secretagogues in the treatment of type 2 diabetes.
Luna B, Hughes AT, Feinglos MN. Luna B, et al. Prim Care. 1999 Dec;26(4):895-915. doi: 10.1016/s0095-4543(05)70138-x. Prim Care. 1999. PMID: 10523467 Review. - Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ, Bailey CJ. Krentz AJ, et al. Drugs. 2005;65(3):385-411. doi: 10.2165/00003495-200565030-00005. Drugs. 2005. PMID: 15669880 Review. - The use of insulin alone and in combination with oral agents in type 2 diabetes.
Buse JB. Buse JB. Prim Care. 1999 Dec;26(4):931-50. doi: 10.1016/s0095-4543(05)70140-8. Prim Care. 1999. PMID: 10523468 Review. - New directions in type 2 diabetes mellitus: an update of current oral antidiabetic therapy.
Brown DL, Brillon D. Brown DL, et al. J Natl Med Assoc. 1999 Jul;91(7):389-95. J Natl Med Assoc. 1999. PMID: 10643211 Free PMC article. Review.
Cited by
- Glucokinase activators and imeglimin: new weaponry in the armamentarium against type 2 diabetes.
Sjöholm Å. Sjöholm Å. BMJ Open Diabetes Res Care. 2024 Aug 30;12(4):e004291. doi: 10.1136/bmjdrc-2024-004291. BMJ Open Diabetes Res Care. 2024. PMID: 39214626 Free PMC article. Review. - Live Cell Monitoring of Phosphodiesterase Inhibition by Sulfonylurea Drugs.
Berisha F, Blankenberg S, Nikolaev VO. Berisha F, et al. Biomolecules. 2024 Aug 10;14(8):985. doi: 10.3390/biom14080985. Biomolecules. 2024. PMID: 39199373 Free PMC article. - Association between the triglyceride glucose index and length of hospital stay in patients with heart failure and type 2 diabetes in the intensive care unit: a retrospective cohort study.
Zhang K, Han Y, Gao YX, Gu FM, Cai T, Gu ZX, Yu ZJ, Min G, Gao YF, Hu R, Huang MX. Zhang K, et al. Front Endocrinol (Lausanne). 2024 May 10;15:1354614. doi: 10.3389/fendo.2024.1354614. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38800470 Free PMC article. - Association of the Reduced Function Met420del Polymorphism of SLC22A1 with Metformin-Induced Gastrointestinal Intolerance in Ethiopian Patients with Type 2 Diabetes Mellitus.
Degaga A, Sirgu S, Huri HZ, Sim MS, Loganadan NK, Kebede T, Tegene B, Engidawork E, Shibeshi W. Degaga A, et al. Pharmgenomics Pers Med. 2024 May 3;17:183-191. doi: 10.2147/PGPM.S457374. eCollection 2024. Pharmgenomics Pers Med. 2024. PMID: 38715682 Free PMC article. - The Role of Selenium Nanoparticles in Addressing Diabetic Complications: A Comprehensive Study.
Satpathy S, Panigrahi LL, Arakha M. Satpathy S, et al. Curr Top Med Chem. 2024;24(15):1327-1342. doi: 10.2174/0115680266299494240326083936. Curr Top Med Chem. 2024. PMID: 38561614 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical